Inovio Pharmaceuticals, Inc. (LON: 0A43)

Market Cap	65.95M
Revenue (ttm)	151.77K
Net Income (ttm)	-84.22M
Shares Out	n/a
EPS (ttm)	-3.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,184
Average Volume	25,810
Open	2.220
Previous Close	2.161
Day's Range	2.160 - 2.279
52-Week Range	1.418 - 11.804
Beta	n/a
RSI	43.37
Earnings Date	Feb 28, 2025

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 122
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A43

Financial Performance

In 2023, Inovio Pharmaceuticals's revenue was $832,010, a decrease of -91.89% compared to the previous year's $10.26 million. Losses were -$135.12 million, -51.71% less than in 2022.

Financial numbers in USD